share_log

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target

Benzinga ·  Aug 28, 2023 06:41

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment